Head-to-head comparison
| Property | Octreotide | Lanreotide |
|---|---|---|
| Category | Other | Other |
| Legal Status | Prescription | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~1.7–1.9 hours (SC); biphasic IV: 10 min + 90 min | ~23–30 days (depot formulation) |
| Mol. Weight | 1,019.24 Da | 1,096.32 Da |
| Side Effects | Nausea, Abdominal cramps, Diarrhea | Diarrhea, Abdominal pain, Cholelithiasis (gallstones) |
Key differences
- Receptor profile: Octreotide and lanreotide are SSTR2 > SSTR5 preferring with minimal SSTR1/3/4 activity; pasireotide binds SSTR1, SSTR2, SSTR3, and SSTR5 with particularly high SSTR5 affinity, a 'multi-receptor' profile.
- Acromegaly first-line: Octreotide LAR and lanreotide depot are the established first-line parenteral somatostatin analogs for post-surgical biochemical control in acromegaly; pasireotide LAR is reserved for patients inadequately controlled on the first-generation analogs.
- Neuroendocrine tumors: Octreotide LAR and lanreotide depot are the standard for symptomatic control of carcinoid syndrome and for antiproliferative benefit in well-differentiated midgut NETs; pasireotide is not the standard NET analog.
- Cushing's disease: Pasireotide is the only somatostatin analog with an FDA indication for Cushing's disease, reflecting its preferential SSTR5 binding on pituitary corticotroph adenomas; octreotide and lanreotide have little role here.
- Hyperglycemia and diabetes: Pasireotide carries a substantial hyperglycemia signal — worsening of glucose tolerance, new-onset diabetes, and DKA have been reported — driven by SSTR5 inhibition on pancreatic β-cells; octreotide and lanreotide have a comparatively mild glycemic profile.
- LAR formulations: Octreotide LAR is a microsphere depot given every 4 weeks intramuscularly; lanreotide Autogel/Depot is a supersaturated gel given every 4 weeks deep subcutaneously; pasireotide LAR is a microsphere depot given every 4 weeks intramuscularly.
- Oral availability: Octreotide is now also available as an oral delayed-release capsule (Mycapssa) for acromegaly maintenance in patients previously responsive to octreotide LAR; lanreotide and pasireotide remain parenteral-only.
The verdict
Octreotide and lanreotide are clinically interchangeable for most purposes and function as the first-line somatostatin analogs for acromegaly and well-differentiated NETs. The choice between them is driven by injection route preference, formulary access, and device familiarity rather than by a decisive pharmacologic gap. Pasireotide sits in a different niche: it is the preferred somatostatin analog for Cushing's disease and a second-line option in acromegaly that remains uncontrolled on first-generation analogs. Its broader receptor profile comes with a hyperglycemia penalty that demands baseline glucose screening, diabetes risk counseling, and active glycemic monitoring during therapy. The emergence of oral octreotide (Mycapssa) has added a meaningful convenience option for stable acromegaly patients, though the injectable depots remain the workhorse formulations.
Frequently asked questions
Octreotide LAR and lanreotide depot are the established first-line parenteral somatostatin analogs for acromegaly when surgery does not produce biochemical control. Comparative data show broadly similar efficacy between them. Pasireotide LAR is typically reserved for patients whose GH and IGF-1 remain uncontrolled on octreotide or lanreotide, reflecting its second-line positioning and less favorable glycemic profile.
Pasireotide's high affinity for SSTR5 is the main driver. SSTR5 is expressed on pancreatic β-cells and on incretin-producing L-cells, and its activation suppresses insulin secretion and incretin output (GLP-1, GIP). Octreotide and lanreotide, with weaker SSTR5 activity, produce a much milder effect on glucose homeostasis. Pasireotide-associated hyperglycemia is managed with baseline glucose screening, metformin, and — where needed — DPP-4 inhibitors or GLP-1 receptor agonists.
LAR stands for long-acting release. For octreotide and pasireotide, the LAR formulation is a microsphere depot — the peptide is encapsulated in biodegradable polymer microspheres that release drug slowly over approximately 4 weeks after intramuscular injection. Lanreotide Autogel/Depot is mechanistically similar but uses a supersaturated aqueous gel delivered deep subcutaneously. The LAR and depot formulations replaced the need for multiple daily subcutaneous injections of the immediate-release versions.
For most clinical purposes — acromegaly maintenance and carcinoid syndrome symptom control — yes. Head-to-head data show broadly similar efficacy between octreotide LAR (4-weekly IM) and lanreotide Autogel/Depot (4-weekly deep SC), and switching between them is routine when access, injection-site tolerance, or device preference changes. Neither has a decisive advantage over the other as a class.
Pasireotide is preferred in two scenarios. First, Cushing's disease — its SSTR5 affinity makes it the only somatostatin analog with a labelled indication for corticotroph adenoma-driven hypercortisolism. Second, acromegaly refractory to octreotide LAR or lanreotide — the broader receptor profile produces additional biochemical control in a meaningful subset of inadequately controlled patients, at the cost of the hyperglycemia risk.
Yes. Octreotide LAR and lanreotide depot produce symptomatic control of flushing and diarrhea in carcinoid syndrome largely through suppression of serotonin and other vasoactive mediators, separately from whatever antiproliferative effect they have on tumor growth. Symptomatic relief typically appears within the first cycles of depot therapy, while antiproliferative benefit is assessed over months using imaging and biomarker trends.
Mycapssa is an oral delayed-release octreotide capsule approved for long-term maintenance therapy in acromegaly patients previously responsive to parenteral somatostatin analogs. It offers a meaningful convenience advantage for stable patients who want to avoid monthly injections. Its role is maintenance, not initiation — patients are typically stabilized on octreotide LAR or lanreotide first, then transitioned. Lanreotide and pasireotide do not have oral counterparts at time of writing.